# SB-480848 In Subjects With Coronary Heart Disease

> **NCT00269048** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 969 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** SB-480848
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00269048
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 969 (ACTUAL)
- **Last updated:** 2016-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269048, "SB-480848 In Subjects With Coronary Heart Disease". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00269048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*